Collaborators:

Ejder P, Jespersen H, Hernberg M, Ny L, Carneiro A, Ellegård S, Mattila K, Bagge RO, Fountoukidis G, Brandberg Y, Mandala M, O Carrigan B, Schilling B, Aranche A, Hamid O, Berglund A, Helgadottir H, Ullenhag G (2026)
Grand SLAM study protocol: a prospective randomised multicentre study of shortened versus standard duration adjuvant immune checkpoint inhibition for stage IIB-C, III and IV cutaneous melanoma
BMC Cancer, 26 (1)
DOI 10.1186/s12885-026-15924-4, PubMed 41896823

Leitzinger N, Falk RS, Jespersen H, Eide NA, Green AC, Robsahm TE, Veierød MB (2026)
Trends in incidence and survival for uveal melanoma in Norway, 1993-2021
Br J Ophthalmol (in press)
DOI 10.1136/bjo-2025-327605, PubMed 41991253

Fager A, Samuelsson M, Olofsson Bagge R, Pivodic A, Bjursten S, Levin M, Jespersen H, Ny L (2025)
Immune checkpoint inhibitor therapy is associated with a decreased risk of developing melanoma brain metastases
BJC Rep, 3 (1), 22
DOI 10.1038/s44276-025-00137-2, PubMed 40217072